A Brief History of Becton, Dickinson and Company (BDX)

Becton, Dickinson and Company, commonly known as BD, is an American multinational medical technology company that has played a pivotal role in advancing healthcare. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company initially focused on manufacturing and selling thermometers and hypodermic needles.

Early Years and Founding

• In 1897, Maxwell Becton and Fairleigh Dickinson founded Becton, Dickinson and Company in New York City.
• The company initially produced medical devices like syringes, needles, and thermometers.
• By 1906, BD had patented a revolutionary hypodermic needle and syringe, setting the foundation for future innovations.

Growth and Expansion

• In the 1920s, BD continued to expand its product line, including the introduction of the first blood collection device.
• The company went public in 1962, listing on the New York Stock Exchange under the ticker symbol BDX.
• During the 1970s and 1980s, BD expanded internationally, establishing a presence in Europe, Latin America, and Asia.

Innovations and Milestones

• In 1995, BD introduced the BD Vacutainer® system, revolutionizing blood sample collection.
• 2004 marked the launch of the BD Viper™ System, an automated molecular testing system that enhanced diagnostic capabilities.
• In 2015, BD completed its acquisition of CareFusion, a significant move that expanded its portfolio to include medication management and infection prevention solutions.

Recent Developments

• In 2017, BD announced its acquisition of C. R. Bard, Inc., further broadening its product offerings in the medical devices sector.
• During the COVID-19 pandemic, BD played a critical role by increasing the production of syringes and diagnostic tests to support global vaccination efforts.
• In 2021, BD launched its first-ever high-throughput molecular diagnostic platform, BD COR™, designed to address a wide range of infectious diseases.

Who Owns Becton, Dickinson and Company (BDX)

Becton, Dickinson and Company (BDX) is a global medical technology company that is publicly traded on the New York Stock Exchange under the ticker symbol BDX. As a publicly traded entity, its ownership is distributed among numerous institutional and individual investors. Here are some key points about its ownership:

• Institutional Investors: A significant portion of BDX's shares are held by institutional investors. These include mutual funds, pension funds, and other large financial organizations that invest on behalf of their clients. Some of the largest institutional shareholders are Vanguard Group, BlackRock, and State Street Corporation. These institutions hold substantial amounts of stock due to their extensive portfolios and have a significant impact on the company's stock price and decisions.
• Individual Shareholders: Apart from institutional investors, BDX's stock is also owned by individual investors. These might include company executives, employees, and independent investors who purchase shares through brokerage accounts. The ownership percentage by individual investors is generally smaller compared to institutional investors but still constitutes an important part of the overall shareholder base.
• Insider Ownership: This includes shares owned by the company's officers, directors, and key executives. Insider ownership is often seen as a positive indicator, aligning the interests of the management with those of the shareholders. In BDX, key executives and board members hold shares, demonstrating their vested interest in the company's performance.
• Public and Retail Investors: Retail investors, who are individual investors that buy and sell shares for their personal accounts, also make up a segment of BDX’s ownership. This group of investors typically buys shares through retail brokerage firms and online trading platforms. Public ownership by retail investors adds to the liquidity and trading volume of the company’s stock.

Becton, Dickinson and Company (BDX) Mission Statement

Becton, Dickinson and Company (BDX) is committed to advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. The company's mission is entrenched in the pursuit of helping all people live healthy lives. This mission drives every aspect of the company's operations and strategies.

• Advancing the World of Health: BDX focuses on innovations and developments that contribute significantly to the health sector, ensuring better outcomes for patients and healthcare providers.
• Improving Medical Discovery: The company invests in research and development to pioneer new medical technologies and treatments that enhance the discovery and understanding of various health conditions.
• Enhancing Diagnostics: BDX is dedicated to offering advanced diagnostic tools that enable accurate and timely disease detection, which is critical for effective treatment and management.
• Optimizing Care Delivery: By providing tools and solutions that streamline the delivery of care, BDX helps healthcare providers offer high-quality, efficient, and patient-centered services.
• Promoting Healthy Lives: The company's ultimate goal is to support the health and well-being of people worldwide, ensuring they have the resources and care needed to maintain a healthy lifestyle.

Through these efforts, BDX remains a pivotal player in the healthcare industry, steadfast in its mission to foster a healthier world.

How Becton, Dickinson and Company (BDX) Works

Becton, Dickinson and Company (BDX), founded in 1897, is a prominent American medical technology company that manufactures and sells medical devices, instrument systems, and reagents. The company's mission is to advance the world of health by improving medical discovery, diagnostics, and the delivery of care. BDX operates across three main business segments: BD Medical, BD Life Sciences, and BD Interventional.

BD Medical focuses on providing solutions to enhance the quality and safety of healthcare. This segment includes the production of needles, syringes, intravenous catheters, and other devices used to deliver medications and fluids. It also provides diabetes care products, pharmaceutical systems, and anesthesiology products.

BD Life Sciences is dedicated to improving clinical outcomes by offering a comprehensive suite of diagnostic systems and research tools. This segment includes molecular diagnostics, cellular analysis, and microbiology solutions, as well as products used in laboratory automation and informatics.

BD Interventional offers innovative solutions for surgical, endovascular, urological, and critical care interventions. This segment encompasses a wide range of devices and technologies designed to improve patient outcomes and enhance the efficiency of care delivery.

The company's operational model is supported by several key components:

• Research and Development (R&D): BDX heavily invests in R&D to drive innovation and bring advanced medical technologies to market. This helps the company stay at the forefront of medical advancements and meet emerging healthcare needs.
• Manufacturing: The company operates numerous manufacturing facilities globally, ensuring the production of high-quality medical devices and products. BDX adheres to strict quality control standards to ensure product safety and reliability.
• Global Distribution: BDX has a robust global distribution network that ensures timely delivery of products to healthcare providers, laboratories, and patients around the world. The company leverages its extensive logistics capabilities to maintain an efficient supply chain.
• Regulatory Compliance: The company operates in a heavily regulated industry and complies with various international and local regulations. BDX's commitment to regulatory compliance ensures the safety and efficacy of its products.
• Customer Support and Education: BDX provides extensive customer support and educational programs to help healthcare professionals effectively use its products and technologies. This includes training, technical support, and informative resources.

BDX's focus on innovation, quality, and global reach enables the company to make significant contributions to healthcare, improving patient outcomes and advancing medical science.

How Becton, Dickinson and Company (BDX) Makes Money

Becton, Dickinson and Company (BDX) is a global medical technology company that generates revenue through a diversified portfolio of products and services in the healthcare sector. The company operates through three primary business segments: Medical, Life Sciences, and Interventional. Each segment contributes to the overall revenue in distinct ways:

• Medical Segment: This segment includes a wide range of products related to medication management and delivery, such as needles, syringes, IV catheters, and medication delivery systems. The Medical segment is further divided into several units:
  • Medication Delivery Solutions: Includes products like needles, syringes, and intravenous catheters.
  • Pharmaceutical Systems: This unit provides prefilled drug delivery systems to the pharmaceutical industry.
  • Diabetes Care: This unit focuses on products designed to assist diabetic patients in managing their condition, such as insulin syringes and pen needles.
• Life Sciences Segment: The Life Sciences segment provides products and services essential for clinical and research laboratories. It focuses on advancing the science of diagnostics and is divided into the following units:
  • Integrated Diagnostic Solutions: Offers diagnostic systems and consumables used in clinical laboratories, including specimen management and diagnostic reagents.
  • Biosciences: Provides instruments, reagents, and software for cellular research and analysis. The products are used in a variety of research applications including pharmaceuticals, biotechnology, and clinical diagnostics.
• Interventional Segment: The Interventional segment focuses on medical devices for a variety of surgical specialties and interventional procedures. This segment includes the following units:
  • Peripheral Intervention: Offers products for minimally invasive procedures, such as stents and balloon catheters.
  • Surgery: Provides surgical instruments and devices for general and specialty surgery.
  • Urology and Critical Care: Includes products for urological and intensive care applications.

BDX also generates income through service offerings that complement its product lines, such as maintenance contracts, training, and consulting services. By leveraging its broad product portfolio and extensive expertise, BDX maintains a robust revenue stream across various aspects of the healthcare industry.